AtaiBeckley Inc. (ETR:B72)
Germany · Delayed Price · Currency is EUR | Market Cap | 1.37B +450.8% |
| Revenue (ttm) | 3.03M +87.2% |
| Net Income | -575.37M |
| EPS | -2.12 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | 3,087 |
| Open | 3.580 |
| Previous Close | 3.560 |
| Day's Range | 3.580 - 3.580 |
| 52-Week Range | 1.706 - 6.000 |
| Beta | n/a |
| RSI | 56.91 |
| Earnings Date | Aug 14, 2026 |
About AtaiBeckley
AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizophr... [Read more]
Financial Performance
In 2025, AtaiBeckley's revenue was $4.09 million, an increase of 1227.60% compared to the previous year's $308,000. Losses were -$660.05 million, 342.2% more than in 2024.
Financial numbers in USD Financial StatementsNews
Psychedelic: Compass Pathways, AtaiBeckley, GH Research report earnings
In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on earnings, a treatment update and an analyst initiation. EARNINGS: On Thursday, GH…
AtaiBeckley reports Q1 EPS (8c), consensus (11c)
Reports Q1 revenue $954,000, consensus $90,910. Srinivas Rao, Co-Founder and Chief Executive Officer of AtaiBeckley (ATAI), said: “Our $209.9 million in cash is expected to provide a runway through ou...
AtaiBeckley Reports First Quarter 2026 Financial Results and Provides Program and Business Update
Phase 3 pivotal program initiation for BPL-003 in treatment-resistant depression on track for Q2 2026 VLS-01 Phase 2 Elumina topline results anticipated in Q4 2026 Consistent, convergent improvements ...
AtaiBeckley Quarterly report: Q1 2026
AtaiBeckley has published its Q1 2026 quarterly earnings report on May 12, 2026.
Analysts see 200%+ upside in these 3 high-risk stocks: here's why?
Some of Wall Street's biggest upside calls are not sitting in the mega-cap names. They are hiding in small, volatile stocks with thin balance sheets, limited operating history and one big event ahead.
These 3 Psychedelic Stocks Activated After Trump's Executive Order
The Trump administration's April 2026 executive order in support of psychedelic drugs may have flown under the radar for many investors in the midst of the Iran war and numerous other high-profile dom...
AtaiBeckley Transcript: Needham Virtual Psychedelics Forum
Psychedelic drug development is accelerating due to regulatory support and political momentum, with late-stage trials underway and commercial readiness targeted for year-end. Companies are addressing clinical, operational, and payer challenges, leveraging expanded infrastructure and new reimbursement models to drive adoption.
AtaiBeckley and PsyPAN Receive a Silver Award in 2026 Patient Participant Index, Reflecting Ongoing Commitment to Participant-Informed Research
NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developi...
AtaiBeckley Proxy statement: Proxy filing
AtaiBeckley filed a proxy statement on April 22, 2026, providing details for shareholder voting and corporate governance matters.
AtaiBeckley Proxy statement: Proxy filing
AtaiBeckley filed a proxy statement on April 22, 2026, providing details for shareholder voting and corporate governance matters.
AtaiBeckley Announces Additional Phase 2a Results for EMP-01 (oral R-MDMA) Showing Large and Consistent Improvements in Social Anxiety Disorder
NEW YORK, April 22, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developi...
This 4/20, Wall Street Is Betting on More Than Marijuana
While many investors focused on the annual 4/20 holiday, expecting the usual buzz around marijuana stocks, a quiet revolution was unfolding in Washington. Over a weekend when most of the market was lo...
How Trump's psychedelics executive order could unlock stalled cannabis reform
The White House psychedelics executive order accelerates research, clinical trials and "Right to Try" access for drugs like psilocybin, MDMA and ibogaine. The order does not change their legal status,...
Psychedelic Stocks Surge After Trump Signs Order Fast-Tracking Drug Research
The only drug named in Trump's executive order is ibogaine, a psychedelic commonly used to treat depression, anxiety and PTSD among veterans. The drug, a Schedule I substance banned in the U.S., has b...
AtaiBeckley price target raised to $15 from $14 at Canaccord
Canaccord analyst Sumant Kulkarni raised the firm’s price target on AtaiBeckley (ATAI) to $15 from $14 and keeps a Buy rating on the shares. The firm updated its model following…
Psychedelic stocks rally with Trump's support
An executive order aims to speed up how quickly psychedelic drugs for mental illness can move through the regulatory process.
Trump Signs Order to Fast-Track Psychedelic Drugs. AtaiBeckley and These Other Stocks Are Soaring.
AtaiBeckley and Compass Pathways are two drugmakers developing psychedelic treatments for depression.
Psychedelic drug makers rally as Trump orders FDA to expedite reviews
Shares of psychedelic drug developers rose in premarket trading on Monday after U.S. President Donald Trump signed an executive order directing health regulators to speed up reviews of psychedelic dr...
AtaiBeckley price target raised to $16 from $11 at Guggenheim
Guggenheim raised the firm’s price target on AtaiBeckley (ATAI) to $16 from $11 and keeps a Buy rating on the shares. The firm’s recent meetings with management reinforced its “conviction”…
AtaiBeckley Transcript: 25th Annual Needham Virtual Healthcare Conference
Late-stage clinical programs focus on short-duration psychedelic therapies for mental health, with BPL-003 entering phase III for TRD and promising phase II data showing rapid, durable effects. Market strategy targets integration into existing Spravato clinics, and top-line phase III results are expected in Q1 2029.
AtaiBeckley to Participate in Upcoming Needham Healthcare Conferences
Dr. Srinivas Rao, Co-Founder and Chief Executive Officer of AtaiBeckley, will participate in the 25th Annual Needham Virtual Healthcare Conference (April 13 - 16) and the Needham Virtual Psychedelics ...
Psychedelic: AtaiBeckley reports publication of BPL-003 study results
In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on a publication of study results, a clinical site network expansion and a…
AtaiBeckley announces peer-reviewed Phase 2a results of BPL-003 study
AtaiBeckley (ATAI) announced peer-reviewed Phase 2a results in CNS Drugs demonstrating that a single intranasal dose of BPL-003, or mebufotenin benzoate, which holds FDA Breakthrough Therapy Designati...
AtaiBeckley's BPL-003 Shows Rapid, Durable Antidepressant Response in Treatment-Resistant Depression Patients on SSRIs; Phase 2a Data Published in CNS Drugs
NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developi...
AtaiBeckley initiated with a Buy at Deutsche Bank
Deutsche Bank last night initiated coverage of AtaiBeckley (ATAI) with a Buy rating and $12 price target The company is well positioned for the psychedelic “renaissance,” the analyst tells investors…